Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10 CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, announced today that it will present initial clinical data...

CALGARY, Alberta, June 05, 2026 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company“) announces that the District Court of The Hague, Netherlands (the “Court”), has issued a judgment in summary proceedings ordering the lifting of the pre-judgment third-party attachments previously obtained by Frontier Holdings Limited (“FHL“) and Spud Energy Pty Limited (“Spud“), wholly-owned subsidiaries of the Company. The attachments were over certain rights of Petroleum Exploration (Private) Limited (“PEL“) under agreements PEL had with KUFPEC Pakistan Holdings B.V. and Kirthar Pakistan B.V. (together “KUFPEC“) and were in support of the enforcement of arbitral awards rendered against PEL and in favour of FHL and Spud. The summary proceedings were initiated...

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) — InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The units began trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “IPVVU” on June 4, 2026. Each...

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) — Argo Corporation (TSXV: ARGH), (OTCQX: ARGHF) (“Argo” or the “Company”), a leader in next-generation transit solutions, announces that it has closed a non-brokered private placement with a strategic investor whose business is related to the manufacturing of potential future vehicle hardware. Argo continues to advance its next-generation public transit platform and evaluate opportunities to develop alignment with partners and investors in support of its long-term vehicle hardware and fleet strategy. The private placement consisted of 1,150,000 common shares issued at a price of $0.40 per common share, for gross proceeds of $460,000. No finder’s fees or commissions were paid in connection with the private placement. The Company intends to use the proceeds from the private placement for working...

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF) announces the continuation and renewal of its investor relations and marketing service engagements with Alliance Advisors Investor Relations (“Alliance Advisors IR”), The Market Link (“Market Link”) and Emerging Markets Consulting (“EMC”). The Market Link Further to the marketing services agreement entered into on November 14, 2025 with The Market Link, the Company and The Market Link entered into an extension of the arrangement for an additional four-month term on March 19, 2026 for total cash compensation of US$110,000. For more information regarding the services provided by The Market Link, refer to the Company’s press release dated January 19, 2026. Emerging Markets Consulting The Company entered into...

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization ACTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on near-patient testing for critical care, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 3,655,917 shares of common stock (or pre-funded warrant in lieu thereof), series G warrants to purchase up to 3,655,917...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) — Purecore Metals Inc. (CSE: PURE) (FSE: J8Y) (“Purecore” or the “Company”) is pleased to announce a non-brokered private placement offering (the “Offering”) of up to 1,500,000 units (the “Units”) at a price of $1.00 per Unit for aggregate gross proceeds of up to $1,500,000. The Offering Each Unit will be comprised of one common share of the Company (a “Common Share”) and one transferable Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional Common Share at a price of $2.00 per Common Share for a period of three years from the closing of...

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetesDANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced new clinical and real‑world...

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descentSHANGHAI and WALTHAM, Mass.,...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist SAN CARLOS, Calif., June 05, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes...